octocrylene 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
3395 6197-30-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • octocrylene
  • octocrilene
ingredient in sunscreens and cosmetics
  • Molecular weight: 361.49
  • Formula: C24H27NO2
  • CLOGP: 6.84
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 0
  • TPSA: 50.09
  • ALOGS: -5.36
  • ROTB: 10
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
July 21, 2006 FDA LOREAL USA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 709.45 15.39 225 9244 24151 63455402
Chronic sinusitis 217.07 15.39 79 9390 12764 63466789
Paraesthesia oral 189.35 15.39 80 9389 19176 63460377
Therapy interrupted 178.28 15.39 90 9379 32365 63447188
Procedural pain 177.40 15.39 79 9390 21490 63458063
Body tinea 110.43 15.39 30 9439 1855 63477698
Vaginal flatulence 106.40 15.39 33 9436 3260 63476293
Therapy cessation 102.15 15.39 61 9408 30396 63449157
Inhibitory drug interaction 98.18 15.39 30 9439 2819 63476734
Proctitis 93.87 15.39 34 9435 5407 63474146
Radiculopathy 92.08 15.39 38 9431 8573 63470980
Infection susceptibility increased 91.93 15.39 30 9439 3491 63476062
Drug ineffective 91.09 15.39 350 9119 1044415 62435138
Female genital tract fistula 89.88 15.39 36 9433 7523 63472030
Therapeutic product effect incomplete 85.25 15.39 99 9370 124957 63354596
Glucose tolerance impaired 73.64 15.39 30 9439 6547 63473006
Vaginal discharge 73.38 15.39 33 9436 9165 63470388
Poor quality sleep 72.27 15.39 42 9427 19893 63459660
Dyspepsia 71.46 15.39 82 9387 102114 63377439
Death 70.25 15.39 165 9304 374216 63105337
Purpura 63.71 15.39 32 9437 11353 63468200
Impaired quality of life 57.95 15.39 32 9437 13751 63465802
Colitis ulcerative 57.17 15.39 40 9429 26051 63453502
Bone density decreased 53.53 15.39 31 9438 14581 63464972
Hyperlipidaemia 50.00 15.39 33 9436 19538 63460015
Impaired work ability 48.41 15.39 31 9438 17444 63462109
Surgery 47.87 15.39 41 9428 35871 63443682
Oral candidiasis 47.74 15.39 34 9435 22764 63456789
Frequent bowel movements 47.44 15.39 34 9435 22988 63456565
Skin disorder 44.12 15.39 36 9433 29471 63450082
Hospitalisation 42.94 15.39 58 9411 85023 63394530
Local anaesthetic systemic toxicity 42.07 15.39 12 9457 887 63478666
Removal of foreign body 41.21 15.39 7 9462 41 63479512
Oral herpes 39.38 15.39 32 9437 26042 63453511
Tracheal deviation 38.45 15.39 8 9461 154 63479399
Pyrexia 38.39 15.39 155 9314 470323 63009230
Rectal haemorrhage 37.06 15.39 41 9428 48989 63430564
Phrenic nerve paralysis 36.93 15.39 8 9461 188 63479365
Weight decreased 33.58 15.39 104 9365 276694 63202859
Colitis 32.30 15.39 38 9431 48490 63431063
Haematochezia 29.31 15.39 38 9431 53506 63426047
Herpes zoster 28.37 15.39 47 9422 82415 63397138
Cellulitis 27.25 15.39 46 9423 81912 63397641
Alopecia 24.27 15.39 10 9459 337526 63142027
Intentional dose omission 24.05 15.39 15 9454 8060 63471493
Foreign body in respiratory tract 23.09 15.39 6 9463 312 63479241
Drug intolerance 22.42 15.39 9 9460 308652 63170901
Infusion related reaction 21.65 15.39 83 9386 245438 63234115
Hepatic enzyme increased 20.29 15.39 3 9466 202325 63277228
Anaphylactic shock 20.02 15.39 21 9448 23612 63455941
Systemic lupus erythematosus 18.99 15.39 4 9465 208914 63270639
Cataract 18.93 15.39 32 9437 57021 63422532
Purtscher retinopathy 18.46 15.39 4 9465 94 63479459
Constipation 18.17 15.39 74 9395 224869 63254684
Jarisch-Herxheimer reaction 17.50 15.39 5 9464 372 63479181
Rheumatoid arthritis 17.47 15.39 8 9461 253811 63225742
Therapeutic product effect decreased 16.95 15.39 4 9465 193183 63286370
Chemical burn 16.90 15.39 5 9464 420 63479133
Abdominal discomfort 16.71 15.39 14 9455 320871 63158682
Foetal exposure during delivery 16.41 15.39 4 9465 160 63479393
Joint swelling 16.21 15.39 15 9454 327651 63151902
Dermatophytosis 15.79 15.39 4 9465 188 63479365
Swelling 15.63 15.39 11 9458 275367 63204186

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 115.70 16.72 213 5173 397836 34553709
Therapy interrupted 107.42 16.72 49 5337 13648 34937897
Anal inflammation 72.31 16.72 20 5366 1280 34950265
Therapy cessation 69.13 16.72 39 5347 16934 34934611
SARS-CoV-2 test negative 62.81 16.72 17 5369 1003 34950542
Proctalgia 49.69 16.72 22 5364 5701 34945844
Accident 49.03 16.72 21 5365 5026 34946519
Surgery 43.17 16.72 27 5359 14130 34937415
Appendicolith 41.17 16.72 22 5364 8579 34942966
Ventricular fibrillation 39.90 16.72 31 5355 22923 34928622
Cardiogenic shock 35.87 16.72 31 5355 26587 34924958
Appendicitis 34.80 16.72 24 5362 14783 34936762
Removal of foreign body 34.72 16.72 6 5380 38 34951507
Haemorrhoids 30.49 16.72 22 5364 14553 34936992
Cardiac arrest 29.51 16.72 53 5333 96106 34855439
Body temperature increased 24.97 16.72 21 5365 17347 34934198
Stress 21.63 16.72 25 5361 30322 34921223
Ascites 21.59 16.72 31 5355 46540 34905005
Hospitalisation 20.91 16.72 34 5352 56868 34894677
Methaemoglobinaemia 19.53 16.72 10 5376 3571 34947974
Administration related reaction 18.14 16.72 4 5382 99 34951446
Constipation 17.94 16.72 54 5332 136928 34814617

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Therapy interrupted 305.06 14.89 134 13320 31207 79699727
Death 215.63 14.89 360 13094 566154 79164780
Macular degeneration 202.55 14.89 75 13379 11221 79719713
Chronic sinusitis 195.69 14.89 76 13378 12950 79717984
Paraesthesia oral 175.08 14.89 80 13374 20391 79710543
Therapy cessation 174.29 14.89 97 13357 37465 79693469
Procedural pain 159.87 14.89 78 13376 23006 79707928
Body tinea 107.25 14.89 30 13424 1824 79729110
Vaginal flatulence 106.05 14.89 32 13422 2543 79728391
Surgery 103.33 14.89 66 13388 32700 79698234
Female genital tract fistula 90.21 14.89 35 13419 5940 79724994
Infection susceptibility increased 86.66 14.89 30 13424 3691 79727243
Inhibitory drug interaction 85.10 14.89 31 13423 4422 79726512
Proctitis 80.81 14.89 33 13421 6399 79724535
Radiculopathy 80.21 14.89 36 13418 8788 79722146
Hospitalisation 76.96 14.89 87 13367 94149 79636785
Therapeutic product effect incomplete 73.08 14.89 104 13350 141541 79589393
Vaginal discharge 72.83 14.89 32 13422 7431 79723503
Anal inflammation 64.21 14.89 19 13435 1411 79729523
Glucose tolerance impaired 64.12 14.89 30 13424 8054 79722880
Removal of foreign body 62.48 14.89 11 13443 71 79730863
Poor quality sleep 60.05 14.89 41 13413 22681 79708253
Dyspepsia 57.81 14.89 81 13373 108606 79622328
Impaired quality of life 52.99 14.89 32 13422 14354 79716580
Bone density decreased 52.57 14.89 31 13423 13316 79717618
SARS-CoV-2 test negative 52.03 14.89 16 13438 1355 79729579
Local anaesthetic systemic toxicity 47.31 14.89 14 13440 1040 79729894
Purpura 46.37 14.89 33 13421 19494 79711440
Hyperlipidaemia 44.09 14.89 36 13418 26057 79704877
Skin disorder 43.52 14.89 40 13414 33903 79697031
Colitis ulcerative 40.81 14.89 39 13415 34703 79696231
Appendicolith 39.40 14.89 22 13432 8529 79722405
Impaired work ability 39.38 14.89 30 13424 19651 79711283
Tracheal deviation 36.58 14.89 8 13446 173 79730761
Oral herpes 36.46 14.89 33 13421 27421 79703513
Proctalgia 36.20 14.89 22 13432 9979 79720955
Accident 36.07 14.89 21 13433 8810 79722124
Ventricular fibrillation 35.92 14.89 35 13419 31891 79699043
Frequent bowel movements 34.39 14.89 33 13421 29506 79701428
Oral candidiasis 34.31 14.89 33 13421 29595 79701339
Anaphylactic shock 34.17 14.89 36 13418 35960 79694974
Pyrexia 32.82 14.89 211 13243 678498 79052436
Constipation 32.24 14.89 113 13341 282937 79447997
Chemical burn 31.60 14.89 9 13445 584 79730350
Phrenic nerve paralysis 31.54 14.89 8 13446 333 79730601
Foreign body in respiratory tract 30.17 14.89 8 13446 397 79730537
Foreign body 30.16 14.89 13 13441 2881 79728053
Appendicitis 27.62 14.89 25 13429 20769 79710165
Methaemoglobinaemia 27.53 14.89 15 13439 5542 79725392
Cardiogenic shock 26.49 14.89 34 13420 41880 79689054
Completed suicide 25.94 14.89 5 13449 245762 79485172
Intentional dose omission 25.91 14.89 17 13437 8800 79722134
Herpes zoster 24.82 14.89 51 13403 93032 79637902
Cardiac arrest 23.41 14.89 73 13381 172023 79558911
Kounis syndrome 22.45 14.89 12 13442 4270 79726664
Rectal haemorrhage 21.77 14.89 43 13411 76257 79654677
Haemorrhoids 20.60 14.89 25 13429 29103 79701831
Abdominal distension 19.36 14.89 54 13400 119596 79611338
Colitis 19.35 14.89 40 13414 73267 79657667
Infusion related reaction 18.94 14.89 83 13371 230154 79500780
Haematochezia 18.80 14.89 44 13410 87601 79643333
Drug intolerance 18.21 14.89 11 13443 264108 79466826
Spinal operation 17.92 14.89 13 13441 7904 79723030
Cataract 17.71 14.89 35 13419 62085 79668849
Purtscher retinopathy 16.97 14.89 4 13450 122 79730812
Injection site infection 16.90 14.89 8 13446 2204 79728730
Cellulitis 16.46 14.89 48 13406 109012 79621922
Weight decreased 15.63 14.89 108 13346 355090 79375844
Alopecia 15.45 14.89 10 13444 231345 79499589
Ascites 15.19 14.89 37 13417 75525 79655409
Hepatic enzyme increased 15.02 14.89 6 13448 182604 79548330
Anaesthetic complication 14.95 14.89 8 13446 2851 79728083

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D05227 KEGG_DRUG
C0257715 UMLSCUI
CHEBI:135526 CHEBI
CHEMBL1201147 ChEMBL_ID
DB09535 DRUGBANK_ID
C088673 MESH_SUPPLEMENTAL_RECORD_UI
22571 PUBCHEM_CID
4719 INN_ID
5A68WGF6WM UNII
77674 RXNORM
004367 NDDF
423007005 SNOMEDCT_US
69296007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Solbar Thirty SPF 30 HUMAN OTC DRUG LABEL 5 0096-0685 CREAM 0.02 g TOPICAL OTC monograph final 8 sections
Solbar Thirty SPF 30 HUMAN OTC DRUG LABEL 5 0096-0685 CREAM 0.02 g TOPICAL OTC monograph final 8 sections
Daily Facial MoisturizerSPF 25 HUMAN OTC DRUG LABEL 4 0096-0721 CREAM 0.02 g TOPICAL OTC monograph final 11 sections
Solbar Fifty SPF50 HUMAN OTC DRUG LABEL 4 0096-0741 CREAM 0.10 g TOPICAL OTC monograph final 8 sections
Solbar Fifty SPF50 HUMAN OTC DRUG LABEL 4 0096-0741 CREAM 0.10 g TOPICAL OTC monograph final 8 sections
Mederma HUMAN OTC DRUG LABEL 3 0259-3192 CREAM 100 mg TOPICAL OTC MONOGRAPH FINAL 13 sections
Mederma HUMAN OTC DRUG LABEL 3 0259-3192 CREAM 100 mg TOPICAL OTC MONOGRAPH FINAL 13 sections
Cetaphil HUMAN OTC DRUG LABEL 2 0299-3928 LOTION 10 g TOPICAL OTC monograph final 10 sections
Cetaphil HUMAN OTC DRUG LABEL 2 0299-3928 LOTION 10 g TOPICAL OTC monograph final 10 sections
Cetaphil Daily Facial Moisturizer with suncreen SPF 35 HUMAN OTC DRUG LABEL 4 0299-4113 LOTION 70 mg TOPICAL OTC monograph final 12 sections
Cetaphil Daily Facial Moisturizer with suncreen SPF 35 HUMAN OTC DRUG LABEL 4 0299-4113 LOTION 70 mg TOPICAL OTC monograph final 12 sections
Cetaphil Healthy Radiance Whipped Day Cream Broad Spectrum SPF 30 HUMAN OTC DRUG LABEL 4 0299-4118 LOTION 80 mg TOPICAL OTC monograph final 12 sections
Cetaphil Healthy Radiance Whipped Day Cream Broad Spectrum SPF 30 HUMAN OTC DRUG LABEL 4 0299-4118 LOTION 80 mg TOPICAL OTC monograph final 12 sections
Cetaphil Oil Absorbing SPF 30 HUMAN OTC DRUG LABEL 3 0299-4123 LOTION 7 g TOPICAL OTC monograph final 8 sections
Cetaphil Oil Absorbing SPF 30 HUMAN OTC DRUG LABEL 3 0299-4123 LOTION 7 g TOPICAL OTC monograph final 8 sections
Differin Oil Absorbing Moisturizer SPF 30 HUMAN OTC DRUG LABEL 3 0299-4133 LOTION 7 g TOPICAL OTC monograph final 9 sections
Cetaphil Oil Absorbing SPF 30 HUMAN OTC DRUG LABEL 3 0299-4134 LOTION 7 g TOPICAL OTC monograph final 8 sections
Cetaphil Healthy Renew Day Cream Broad Spectrum SPF 30 HUMAN OTC DRUG LABEL 4 0299-4136 LOTION 95 mg TOPICAL OTC monograph final 12 sections
Cetaphil PRO Oil Absorbing SPF 30 HUMAN OTC DRUG LABEL 3 0299-4313 LOTION 7 g TOPICAL OTC monograph final 8 sections
Differin Oil Absorbing Moisturizer SPF 30 HUMAN OTC DRUG LABEL 3 0299-4607 LOTION 7 g TOPICAL OTC monograph final 9 sections
Differin Oil Absorbing Moisturizer SPF 30 HUMAN OTC DRUG LABEL 3 0299-4607 LOTION 7 g TOPICAL OTC monograph final 9 sections
Cetaphil Daily Facial Moisturizer with suncreen SPF 50 HUMAN OTC DRUG LABEL 5 0299-4930 LOTION 70 mg TOPICAL OTC monograph final 11 sections
Cetaphil Daily Facial Moisturizer with suncreen SPF 50 HUMAN OTC DRUG LABEL 5 0299-4930 LOTION 70 mg TOPICAL OTC monograph final 11 sections
Almay Healthy Biome Makeup HUMAN OTC DRUG LABEL 5 0311-0723 EMULSION 5 mg TOPICAL OTC monograph final 7 sections
Blue Lizard Regular HUMAN OTC DRUG LABEL 4 0316-2010 LOTION 20.40 mg TOPICAL OTC monograph final 8 sections
Blue Lizard Sport Original Sunscreen HUMAN OTC DRUG LABEL 4 0316-2019 LOTION 20.40 mg TOPICAL OTC monograph not final 8 sections
Blue Lizard Sport Sunscreen HUMAN OTC DRUG LABEL 2 0316-2021 LOTION 41.80 mg TOPICAL OTC monograph not final 9 sections
Blue Lizard Sport Sunscreen HUMAN OTC DRUG LABEL 2 0316-2021 LOTION 41.80 mg TOPICAL OTC monograph not final 9 sections
Blue Lizard Kids Sunscreen HUMAN OTC DRUG LABEL 2 0316-2061 LOTION 41.80 mg TOPICAL OTC monograph not final 8 sections
Blue Lizard Active Sunscreen HUMAN OTC DRUG LABEL 2 0316-2071 LOTION 41.80 mg TOPICAL OTC monograph not final 9 sections